Skip to main content
. 2021 Feb 6;9(2):132. doi: 10.3390/vaccines9020132

Figure 4.

Figure 4

Heterologous vaccine strategy elicits SARS-CoV-2 neutralizing antibody responses. Groups of C57BL/5 mice were either unvaccinated (PBS) or immunized with pQAC/MVA-CoV (I.N). Serum and BAL samples were collected 3 weeks post boost. (a) 50% serum neutralization titer of pseudo-virus expressing SARS-CoV-2 spike, (b) serum neutralization titer of wild-type SARS-CoV-2, isolate USA-WA1/2020, (c) 50% BAL neutralization titer of pseudo-virus expressing SARS-CoV-2 spike, and (d) BAL neutralization titer of wild-type SARS-CoV-2, isolate USA-WA1/2020. Significance (*, p < 0.05; **, p < 0.01) was determined by one-way ANOVA. Data show mean ± SEM. The dotted line indicates the lower limit of detection.